Syndax Pharmaceuticals (NASDAQ:SNDX) Lowered to “Hold” at BidaskClub

BidaskClub cut shares of Syndax Pharmaceuticals (NASDAQ:SNDX) from a buy rating to a hold rating in a report published on Wednesday, April 11th.

Other equities analysts have also recently issued research reports about the stock. B. Riley reaffirmed a buy rating and set a $40.00 price target on shares of Syndax Pharmaceuticals in a research report on Thursday, January 18th. Zacks Investment Research upgraded shares of Syndax Pharmaceuticals from a hold rating to a buy rating and set a $10.00 price objective on the stock in a research note on Wednesday, January 10th. Morgan Stanley dropped their price objective on shares of Syndax Pharmaceuticals from $25.00 to $24.00 and set an overweight rating on the stock in a research note on Wednesday, March 14th. Finally, ValuEngine upgraded shares of Syndax Pharmaceuticals from a strong sell rating to a sell rating in a research note on Tuesday, March 20th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the company. Syndax Pharmaceuticals currently has a consensus rating of Buy and a consensus target price of $23.86.

How to Become a New Pot Stock Millionaire

Shares of SNDX stock opened at $11.23 on Wednesday. Syndax Pharmaceuticals has a one year low of $7.41 and a one year high of $15.43.

Syndax Pharmaceuticals (NASDAQ:SNDX) last issued its quarterly earnings results on Monday, March 5th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.04). Syndax Pharmaceuticals had a negative return on equity of 63.51% and a negative net margin of 2,884.34%. The company had revenue of $1.19 million for the quarter, compared to the consensus estimate of $0.75 million. The firm’s revenue for the quarter was up 290.2% compared to the same quarter last year. analysts expect that Syndax Pharmaceuticals will post -3.52 earnings per share for the current year.

In other Syndax Pharmaceuticals news, insider Peter Ordentlich sold 7,500 shares of the firm’s stock in a transaction that occurred on Tuesday, April 3rd. The shares were sold at an average price of $15.00, for a total value of $112,500.00. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 24.10% of the stock is owned by corporate insiders.

Large investors have recently made changes to their positions in the business. BVF Inc. IL acquired a new stake in shares of Syndax Pharmaceuticals in the fourth quarter valued at approximately $28,326,000. Candriam Luxembourg S.C.A. acquired a new stake in shares of Syndax Pharmaceuticals in the fourth quarter valued at approximately $613,000. OxFORD Asset Management LLP increased its stake in shares of Syndax Pharmaceuticals by 75.0% in the third quarter. OxFORD Asset Management LLP now owns 48,442 shares of the company’s stock valued at $574,000 after purchasing an additional 20,753 shares during the period. Paloma Partners Management Co acquired a new stake in shares of Syndax Pharmaceuticals in the fourth quarter valued at approximately $144,000. Finally, Dimensional Fund Advisors LP increased its stake in shares of Syndax Pharmaceuticals by 302.2% in the third quarter. Dimensional Fund Advisors LP now owns 55,280 shares of the company’s stock valued at $647,000 after purchasing an additional 41,537 shares during the period. Institutional investors own 69.55% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was posted by Week Herald and is the sole property of of Week Herald. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://weekherald.com/2018/04/19/syndax-pharmaceuticals-sndx-downgraded-by-bidaskclub-to-hold.html.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer.

Analyst Recommendations for Syndax Pharmaceuticals (NASDAQ:SNDX)

Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply